newsfilter
← Latest News
GlobeNewswire·

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

No quantifiable VYN201 plasma concentrations above the assay lower limit of quantification supports "soft" drug approach for topical pan-BD BET inhibitor All hematological parameters, including platelet counts, were